Astellas asks women 'What's VMS' in its latest TV ad.
What causes hot flashes? Astellas ramps up educational campaign ahead of FDA decision
Astellas’ fezolinetant isn’t due for an FDA decision until February in vasomotor symptoms (VMS) associated with menopause — but the pharma company isn’t waiting until then to educate women about what’s causing their hot flashes.
While up to 80% of women will experience hot flashes in their lifetimes, many feel unprepared when they enter menopause and 70% go untreated, according to Astellas’ senior director of marketing and women’s health Jill Jaroch. Some don’t even know the technical term behind hot flashes, VMS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
